De Rubertis Francesco's Form 4 filing
Centessa Pharmaceuticals plc (CNTA) · filed Dec 6, 2021
- Accession no.
- 0000899243-21-046972
- Filed
- Dec 6, 2021
- Trade date
- Dec 2, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $440.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| De Rubertis FrancescoCIK 0001601521 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2021 | Ordinary Shares | PPurchaseAcquired | +33,530 | $12.82 | +$429,854.6 | 3,936,970 | Indirect | |
| Dec 2, 2021 | Ordinary Shares | PPurchaseAcquired | +796 | $12.82 | +$10,204.72 | 93,526 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.